ArticleIntestinal Failure (New York, N.Y.)
Combination of anti-TNFα therapy and surgical resection for severe chronic intestinal rejection: A case report.
Article in Intestinal Failure (New York, N.Y.). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Acute cellular rejection (ACR) is a well-recognised cause of graft failure in intestinal transplant (ITx) recipients. Management of ACR is with intravenous (IV) steroids, increased immunosuppression and T-cell depleting therapies. Use of alternative therapies such as anti-tumour necrosis factor alpha (TNFα) agents in steroid-refractory cases should be considered. Case report: A 44-year-old male who received a combined liver-intestinal transplant with ACR unresponsive to IV steroids and anti-thymocyte globulin (ATG), which evolved into chronic rejection (CR). His symptoms were predominantly obstructive with endoscopic similarities to stricturing Crohn's disease. He was successfully managed with infliximab followed by segmental graft resection. With ongoing maintenance infliximab he has remained clinically well with enteral autonomy and no recurrence of rejection. Conclusion: Alternative therapies for management of severe ACR unresponsive to traditional management should be considered in ITx patients. There are increasing numbers of case reports to support the use of anti-TNFα therapy in these cases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.